Physician profile
Ramesh Koka
NPI 1528185162
$8,272.81
in general payments reported to CMS, 2019-2025
34 companies · $1,196 in 2025
The $1,196 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $708 · 2020: $660 · 2021: $1,662 · 2022: $1,548 · 2023: $1,221 · 2024: $1,277 · 2025: $1,196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,684 · Education: $10.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,683.68 |
| Education | $10.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,566.67 | 2019-2025 | |
| Janssen Biotech, INC. | $897.56 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $696.07 | 2019-2025 | |
| Celgene Corporation | $509.04 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $489.38 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $312.87 | 2020-2025 | Entyvio, Gattex |
| Genzyme Corporation | $286.56 | 2022-2025 | |
| Boston Scientific Corporation | $195.32 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $190.37 | 2020-2024 | Linzess |
| Qol Medical, LLC | $106.04 | 2022-2023 | Sucraid |
| Intercept Pharmaceuticals, INC. | $103.76 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $78.80 | 2024-2025 | Voquezna |
| Shire North American Group INC | $64.76 | 2019 | |
| Pfizer INC. | $63.14 | 2019-2021 | |
| Amgen INC. | $62.12 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $58.33 | 2019 | |
| Daiichi Sankyo INC. | $57.83 | 2019-2021 | |
| Madrigal Pharmaceuticals | $52.23 | 2024 | Resmetirom |
| Redhill Biopharma INC. | $52.11 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $45.60 | 2022-2023 | Dupixent |
| Ipsen Biopharmaceuticals, INC | $43.14 | 2024 | Iqirvo, Bylvay |
| Mylan Institutional INC. | $37.58 | 2023 | Hulio |
| Merck Sharp & Dohme LLC | $36.81 | 2021-2024 | Dificid |
| Intuitive Surgical, INC. | $35.70 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $35.19 | 2022-2023 | |
| Ardelyx, INC. | $34.61 | 2025 | Ibsrela |
| Aimmune Therapeutics, INC. | $34.04 | 2023 | |
| Nestle Healthcare Nutrition INC. | $23.90 | 2021 | |
| Alnylam Pharmaceuticals INC. | $23.78 | 2021 | |
| Vivus LLC | $19.06 | 2024 | Qsymia |
| Alexion Pharmaceuticals, INC. | $17.66 | 2022 | |
| Novo Nordisk INC | $17.22 | 2025 | Wegovy |
| Ferring Pharmaceuticals INC. | $15.08 | 2024 | Rebyota |
| Janssen Pharmaceuticals, INC | $10.48 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramesh Koka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.